Fulcrum Therapeutics, Inc., a biopharmaceutical company based in Cambridge, Mass., announced on Sept. 12, 2025, that they have granted non-statutory stock options to a new employee. The company, listed on Nasdaq under the ticker symbol FULC, focuses on developing small molecules to help patients with rare genetic diseases. The stock options were granted under the company's 2022 Inducement Stock Incentive Plan as part of the new employee agreement, complying with Nasdaq Listing Rule 5635(c)(4). This move aims to enhance the employee's engagement and align their interests with the company's success.